04/28/2025 | Press release | Distributed by Public on 04/27/2025 19:11
Actimab-A AACR 2025: Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute[...]
